Insights and Media
Commentary, podcast appearances, and thought leadership on federal health policy, advocacy, and healthcare strategy
Andrew shares insights into Medicate Advantage Policy at XYZ event
“There is real bipartisan unease around consolidation and lack of transparency in the system,” he said. “All those things could get thrown into the conversation in a way that many on Wall Street may not be expecting.”
Election Year Or Not, Five Health Policy Items Still On DC’s Menu + The Earthquake That Is The Fall of Chevron
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Amet aliquam id diam maecenas ultricies mi eget mauris.
Three New Themes Coursing Through Our National Health Policy Debate
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Amet aliquam id diam maecenas ultricies mi eget mauris.
After a Decade-Plus of Operating, Some Aspects of The Medicare Shared Savings Program Are Being Teed Up For Modernization
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Amet aliquam id diam maecenas ultricies mi eget mauris.
Andrew Schwab Quoted in The Wall Street Journal on Medicare Advantage Policy
While investors are probably right to assume some easing up of regulatory scrutiny under Trump, they shouldn’t expect a total letup. There is at least some support on both sides of the aisle to tackle the myriad problems with America’s healthcare system, says Andrew Schwab, founder of Washington-based Platform Government Strategies.
“There is real bipartisan unease around consolidation and lack of transparency in the system,” he said. “All those things could get thrown into the conversation in a way that many on Wall Street may not be expecting.”
Andrew speaks to Podnosis about how Congress may approach healthcare reform under Trump
With the election over and President Donald Trump officially inaugurated, all eyes in healthcare are turning toward how the sector might change. But as the first two weeks of his second term showed, keeping up with Trump’s actions—and their ramifications—requires full-time focus.
